Back to News
Market Impact: 0.35
Abbisko's Lavengratinib Shows Early Height-Growth Benefit In Phase II Achondroplasia Study
Source: Nasdaq
Healthcare & Biotech
Abbisko Therapeutics reported preliminary Phase II results showing lavengratinib (ABSK061) improved growth rates in children with achondroplasia. The investigational therapy also maintained a favorable safety profile, supporting its clinical development outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Why is Labcorp stock sliding today?
- Why is Quest Diagnostics stock sliding today?
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Is an AI Research Agent?
- Bitcoin's 52% Crash Proves It's a Tech Stock: Here's What That Means for Portfolio Construction